Merck’s WINREVAIR Approved by the European Commission for PAH in Adults with Functional Class II-III
Merck has secured European Commission (EC) approval for WINREVAIR™ (sotatercept), marking it as the first activin signaling inhibitor therapy for pulmonary arterial hypertension (PAH) approved across all 27 EU member states, plus Iceland, Liechtenstein, and Norway. WINREVAIR is indicated for adult patients with WHO Functional Class II to III PAH and is designed to improve exercise capacity by balancing pro- and anti-proliferative signaling in vascular cells. This approval is based on positive results from the Phase III STELLAR trial.
Dr. Joerg Koglin from Merck ...